Se‐Hoon Lee

32.6k total citations · 5 hit papers
617 papers, 17.4k citations indexed

About

Se‐Hoon Lee is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Se‐Hoon Lee has authored 617 papers receiving a total of 17.4k indexed citations (citations by other indexed papers that have themselves been cited), including 315 papers in Oncology, 286 papers in Pulmonary and Respiratory Medicine and 109 papers in Cancer Research. Recurrent topics in Se‐Hoon Lee's work include Lung Cancer Treatments and Mutations (196 papers), Lung Cancer Research Studies (114 papers) and Cancer Genomics and Diagnostics (82 papers). Se‐Hoon Lee is often cited by papers focused on Lung Cancer Treatments and Mutations (196 papers), Lung Cancer Research Studies (114 papers) and Cancer Genomics and Diagnostics (82 papers). Se‐Hoon Lee collaborates with scholars based in South Korea, United States and Ethiopia. Se‐Hoon Lee's co-authors include Keunchil Park, Jin Seok Ahn, Dae Seog Heo, Myung‐Ju Ahn, Tae Min Kim, Jong‐Mu Sun, Bhumsuk Keam, Dong‐Wan Kim, Doo Hyun Chung and Yung‐Jue Bang and has published in prestigious journals such as New England Journal of Medicine, JAMA and Nature Communications.

In The Last Decade

Se‐Hoon Lee

586 papers receiving 17.1k citations

Hit Papers

Perioperative Pembrolizum... 2017 2026 2020 2023 2023 2019 2017 2024 2025 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
    2023 460 citations Heather A. Wakelee, Moïshe Liberman et al. profile →
  2. DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load
    2019 322 citations Jong‐Mu Sun, Jin Seok Ahn et al. profile →
  3. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study
    2017 300 citations Se‐Hoon Lee et al. Journal of Clinical Oncology profile →
  4. LORIS robustly predicts patient outcomes with immune checkpoint blockade therapy using common clinical, pathologic and genomic features
    2024 50 citations Se‐Hoon Lee et al. profile →
  5. Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through IL-6/Jak/Stat3 in PD-L1-high lung cancer
    2025 25 citations Soo Hyun Lee, Se‐Hoon Lee et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Se‐Hoon Lee 9.1k 8.7k 4.1k 3.0k 1.8k 617 17.4k
Igor Bondarenko 13.3k 1.5× 9.0k 1.0× 3.3k 0.8× 3.6k 1.2× 1.2k 0.7× 317 17.7k
Nancy U. Lin 11.2k 1.2× 7.7k 0.9× 3.5k 0.8× 4.0k 1.3× 941 0.5× 375 17.2k
Ahmad Awada 9.5k 1.0× 4.8k 0.6× 5.2k 1.3× 3.0k 1.0× 1.6k 0.9× 542 16.2k
Martin Schüler 9.7k 1.1× 7.2k 0.8× 8.9k 2.2× 2.9k 1.0× 1.6k 0.9× 478 20.5k
Benjamin Besse 12.2k 1.3× 10.4k 1.2× 5.6k 1.4× 3.8k 1.2× 971 0.5× 708 18.8k
Lesley Seymour 13.8k 1.5× 13.6k 1.6× 5.3k 1.3× 3.8k 1.2× 1.8k 1.0× 258 22.2k
Jin Seok Ahn 8.6k 0.9× 7.8k 0.9× 3.2k 0.8× 3.0k 1.0× 962 0.5× 452 13.5k
Tae Min Kim 7.6k 0.8× 5.5k 0.6× 3.2k 0.8× 1.8k 0.6× 785 0.4× 462 13.4k
William Novotny 12.5k 1.4× 5.7k 0.6× 8.0k 1.9× 3.8k 1.2× 2.1k 1.2× 110 22.6k
Byoung Chul Cho 13.2k 1.5× 12.9k 1.5× 5.7k 1.4× 3.2k 1.1× 2.2k 1.2× 689 19.8k

Countries citing papers authored by Se‐Hoon Lee

Since Specialization
Citations

This map shows the geographic impact of Se‐Hoon Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Se‐Hoon Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Se‐Hoon Lee more than expected).

Fields of papers citing papers by Se‐Hoon Lee

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Se‐Hoon Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Se‐Hoon Lee. The network helps show where Se‐Hoon Lee may publish in the future.

Co-authorship network of co-authors of Se‐Hoon Lee

This figure shows the co-authorship network connecting the top 25 collaborators of Se‐Hoon Lee. A scholar is included among the top collaborators of Se‐Hoon Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Se‐Hoon Lee. Se‐Hoon Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Boumelha, Jesse, Nourdine Bah, Hongui Cha, et al.. (2024). CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer. Cancer Research. 84(14). 2231–2246. 10 indexed citations
2.
Kim, Young Saing, Keon Uk Park, Jang Ho Cho, et al.. (2024). Clinical Outcomes of Maintenance Durvalumab After Definitive Concurrent Chemoradiotherapy in Unresectable Locally Advanced Stage III NSCLC According to EGFR and ALK Status: Korean Cancer Study Group LU-22-18. JTO Clinical and Research Reports. 5(12). 100734–100734. 1 indexed citations
3.
4.
Zaheer, Javeria, et al.. (2024). 99mTc-DMSA and 99mTc-DTPA identified renal dysfunction due to microplastic polyethylene in murine model. Chemosphere. 364. 143108–143108. 3 indexed citations
5.
Garassino, Marina Chiara, Heather A. Wakelee, Jonathan Spicer, et al.. (2024). Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(16_suppl). 8012–8012. 2 indexed citations
6.
7.
Cabanillas, Maria E., Marcia S. Brose, Ray McDermott, et al.. (2024). Long-term efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion thyroid carcinoma (TC).. Journal of Clinical Oncology. 42(16_suppl). 6095–6095. 4 indexed citations
8.
Park, Sehhoon, Hyun Ae Jung, Se‐Hoon Lee, et al.. (2024). A phase II trial of neoadjuvant nivolumab, docetaxel, and cisplatin followed by surgery and radiation therapy for resectable high-grade salivary gland carcinoma.. Journal of Clinical Oncology. 42(16_suppl). e18061–e18061.
9.
Park, Sehhoon, Hyun Ae Jung, Jong‐Mu Sun, et al.. (2024). Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation–Positive Non–Small Cell Lung Cancer (BLOSSOM). Journal of Clinical Oncology. 42(23). 2747–2756. 23 indexed citations
10.
Wakelee, Heather A., Moïshe Liberman, Terufumi Kato, et al.. (2023). KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.. Journal of Clinical Oncology. 41(17_suppl). LBA100–LBA100. 11 indexed citations
11.
Kim, Hana, Sehhoon Park, Hyun Ae Jung, et al.. (2023). Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Cancer Research and Treatment. 55(4). 1104–1112. 14 indexed citations
12.
Razak, Albiruni Ryan Abdul, Hung‐Ming Wang, Jang‐Yang Chang, et al.. (2023). A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Targeted Oncology. 18(6). 853–868. 10 indexed citations
13.
Park, Sehhoon, Yu Jung Kim, Young Joo Min, et al.. (2023). Biomarker‐driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer. Cancer. 130(4). 541–552. 15 indexed citations
14.
Kim, Kyung Hwan, Jinhyun Cho, Bo Mi Ku, et al.. (2019). The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors. Clinical Cancer Research. 25(7). 2144–2154. 132 indexed citations
15.
Park, Sehhoon, Hayoon Lee, Boram Lee, et al.. (2019). DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC. Journal of Thoracic Oncology. 14(9). 1640–1650. 58 indexed citations
16.
Noh, Ka‐Won, Insuk Sohn, Ji‐Young Song, et al.. (2018). Integrin β3 Inhibition Enhances the Antitumor Activity of ALK Inhibitor in ALK -Rearranged NSCLC. Clinical Cancer Research. 24(17). 4162–4174. 17 indexed citations
17.
Lee, Se‐Hoon, Jae‐Kyung Won, Dong Soo Lee, et al.. (2017). Analysis of Fifty Hotspot Mutations of Lung Squamous Cell Carcinoma in Never-smokers. Journal of Korean Medical Science. 32(3). 415–415. 9 indexed citations
18.
Yang, Yaewon, Tae Min Kim, Yong‐Oon Ahn, et al.. (2016). Phase I Study of Random Healthy Donor–Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors. Cancer Immunology Research. 4(3). 215–224. 128 indexed citations
19.
Kim, Tae Min, Dong‐Wan Kim, Soyeon Kim, et al.. (2015). Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1 -Rearranged Non–Small Cell Lung Cancer. Clinical Cancer Research. 21(10). 2379–2387. 99 indexed citations
20.
Lee, Ji Yun, Jong‐Mu Sun, Sung Hee Lim, et al.. (2015). A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non–Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib. Clinical Cancer Research. 22(9). 2139–2145. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Igor Bondarenko Breakdown of academic impact, for papers by Nancy U. Lin Breakdown of academic impact, for papers by Ahmad Awada Breakdown of academic impact, for papers by Martin Schüler Breakdown of academic impact, for papers by Benjamin Besse Breakdown of academic impact, for papers by Lesley Seymour Breakdown of academic impact, for papers by Jin Seok Ahn Breakdown of academic impact, for papers by Tae Min Kim Breakdown of academic impact, for papers by William Novotny Breakdown of academic impact, for papers by Byoung Chul Cho
Rankless by CCL
2026